Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
The U.S. should assess the economic value of drugs rather than leave it up to other countries
Why are prescription drugs are often priced lower overseas? Many countries perform detailed assessments of the economic value of drugs and their benefits, and this could work in the U.S., says William Padula
-
Mortality Risk, Insurance, and the Value of Life
People with shorter life expectancies place more value on increases in survival than people who anticipate longer life spans.
-
The Bigger Message Behind Amgen’s Decision to Slash Cost of its Repatha Cholesterol Drug
Drug companies look to haggle less and sell more, and that could cost Express Scripts, CVS Health and UnitedHealth writes Goldman in MarketWatch.
-
White House Signs Bills Banning Gag Clauses, Schaeffer Center Research Pivotal in Discussion
Schaeffer Center report found 23 percent of private claims analyzed involved a copayment that exceeded the insurer’s cost of the drug.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
A New Model for Pricing Drugs of Uncertain Efficacy
Goldman, Van Nuys and colleagues propose a three-part pricing (TPP) model that ties prices to value but removes the need to monitor efficacy in each patient. The model creates a tiered system, with prices varying over fixed time intervals.
Categorized in -
Remarks on Medicare Drug Pricing Proposals by Health and Human Services Secretary Alex Azar
On October 26, U.S. Secretary of Health and Human Services Alex Azar visited Brookings to deliver remarks on a top administration priority. After delivering his prepared remarks he sat down for a discussion with Paul Ginsburg.
-
Generic Drug Price Hikes And Out-Of-Pocket Spending For Medicare Beneficiaries
The share of generic drugs that at least doubled in price increased fourfold according to the Health Affairs study. But, this share is still a small percentage of the generic market.
Categorized in -
Seminar Series: Chirantan Chatterjee
Chirantan Chatterjee is an associate professor of business policy and economics at the Indian Institute of Management, Ahmedabad. His research focuses on the economics of innovation, applied microeconomics, pharmaceutical economics, and global health.
-
Do Price Spikes on Some Generic Drugs Indicate Problems in the Generics Market?
Despite the overall success of the generic drug market, sudden price hikes are becoming more common according to new Schaeffer Center study
Categorized in -
Trump Might Actually Lower Drug Prices
Dana Goldman and Anupam Jena write in The Washington Post that the Trump administration may succeed in lowering drug prices by fostering competition and innovation, and possibly ending kickbacks in the supply chain.
Categorized in